Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.

[1]  M. Cappellini,et al.  Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia , 2015, British journal of haematology.

[2]  M. Cappellini,et al.  Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox , 2014, European journal of haematology.

[3]  M. Cappellini,et al.  Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study , 2013, Annals of Hematology.

[4]  M. Cappellini,et al.  Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia. , 2013, Blood cells, molecules & diseases.

[5]  S. Rivella,et al.  Non-transfusion-dependent thalassemias , 2013, Haematologica.

[6]  Vip Viprakasit,et al.  Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients , 2013, American journal of hematology.

[7]  E. Vichinsky,et al.  Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT) , 2013 .

[8]  Vip Viprakasit,et al.  Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. , 2012, Blood.

[9]  D. Weatherall.  The definition and epidemiology of non-transfusion-dependent thalassemia. , 2012, Blood reviews.

[10]  S. Rivella.  The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. , 2012, Blood reviews.

[11]  M. Cappellini,et al.  Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia , 2011, Haematologica.

[12]  N. Siritanaratkul,et al.  Effectiveness of deferiprone in transfusion‐independent beta‐thalassemia/HbE patients , 2011, Hematology.

[13]  E. Vichinsky,et al.  Heterogeneity of hemoglobin H disease in childhood. , 2011, The New England journal of medicine.

[14]  E. Gotsis,et al.  Deferasirox administration for the treatment of non‐transfusional iron overload in patients with thalassaemia intermedia , 2010, British journal of haematology.

[15]  O. Blin,et al.  Orphandev, French Clinical Trials Network dedicated to Orphan drugs and therapeutics development for rare diseases , 2010, Orphanet Journal of Rare Diseases.

[16]  O. Solberg,et al.  E-learning for carers , 2010, Orphanet Journal of Rare Diseases.

[17]  Raffaella Origa,et al.  BETA THALASSEMIA , 2018, The Professional Medical Journal.

[18]  M. Cappellini,et al.  Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias , 2010, Haematologica.

[19]  S. Fucharoen,et al.  Hb H disease: clinical course and disease modifiers. , 2009, Hematology. American Society of Hematology. Education Program.

[20]  M. Cappellini,et al.  Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia , 2008, Haematologica.

[21]  E. Vichinsky,et al.  Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients , 2007, Pediatric blood & cancer.

[22]  E. Vichinsky.  Hemoglobin e syndromes. , 2007, Hematology. American Society of Hematology. Education Program.

[23]  M. Cappellini,et al.  Thalassemia intermedia: revisited. , 2006, Blood cells, molecules & diseases.

[24]  V. Chan,et al.  Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease , 2006, British journal of haematology.

[25]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[26]  G. Sanna,et al.  Iron overload and desferrioxamine chelation therapy in β-thalassemia intermedia , 1981, European Journal of Pediatrics.

[27]  A. Hoffbrand,et al.  Clinical trial of deferiprone iron chelation therapy in β‐thalassaemia/haemoglobin E patients in Thailand , 2003, British journal of haematology.

[28]  M. Kami,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[29]  C. McLaren,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[30]  D. Weatherall,et al.  Iron balance and the management of iron overload in beta-thalassemia intermedia. , 1988, Birth defects original article series.

[31]  M. Cazzola,et al.  Iron metabolism in thalassemia. , 1988, Birth defects original article series.

[32]  J. Clegg,et al.  Heterogeneity and origins of the alpha-thalassemias. , 1987, Birth defects original article series.

[33]  S. De Virgiliis,et al.  Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. , 1981, European journal of pediatrics.

[34]  D. Weatherall,et al.  IRON ABSORPTION AND LOADING IN β-THALASSÆMIA INTERMEDIA , 1979, The Lancet.

[35]  V. Beral,et al.  MALIGNANT-MELANOMA AND FLUORESCENT LIGHTING - REPLY , 1972 .